PLN 2.37
(-1.25%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | - PLN | 0.0% |
2022 | - PLN | -100.0% |
2021 | 139.17 Thousand PLN | -51.22% |
2020 | 285.31 Thousand PLN | -33.76% |
2019 | 430.71 Thousand PLN | 104.0% |
2018 | -10.77 Million PLN | 0.0% |
2017 | - PLN | 0.0% |
2016 | - PLN | 0.0% |
2015 | - PLN | -100.0% |
2014 | 1.3 Million PLN | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | - PLN | 0.0% |
2024 Q1 | - PLN | 0.0% |
2023 Q2 | - PLN | 0.0% |
2023 Q4 | - PLN | 0.0% |
2023 Q1 | - PLN | 0.0% |
2023 Q3 | - PLN | 0.0% |
2023 FY | - PLN | 0.0% |
2022 Q1 | 139.17 Thousand PLN | 0.0% |
2022 FY | - PLN | -100.0% |
2022 Q4 | - PLN | -100.0% |
2022 Q3 | 139.17 Thousand PLN | 0.0% |
2022 Q2 | 139.17 Thousand PLN | -0.0% |
2021 Q3 | 285.31 Thousand PLN | 0.0% |
2021 Q2 | 285.31 Thousand PLN | 0.0% |
2021 Q1 | 285.31 Thousand PLN | 0.0% |
2021 FY | 139.17 Thousand PLN | -51.22% |
2021 Q4 | 139.17 Thousand PLN | -51.22% |
2020 Q1 | 438.75 Thousand PLN | 1.87% |
2020 Q4 | 285.31 Thousand PLN | 271.26% |
2020 Q3 | 76.85 Thousand PLN | 0.0% |
2020 FY | 285.31 Thousand PLN | -33.76% |
2020 Q2 | - PLN | -100.0% |
2019 Q3 | - PLN | 0.0% |
2019 Q1 | 23.85 Thousand PLN | 100.22% |
2019 FY | 430.71 Thousand PLN | 104.0% |
2019 Q4 | 430.71 Thousand PLN | 0.0% |
2019 Q2 | - PLN | -100.0% |
2018 Q1 | - PLN | 0.0% |
2018 Q4 | -10.77 Million PLN | -23458.42% |
2018 Q2 | 56.92 Thousand PLN | 0.0% |
2018 Q3 | 46.11 Thousand PLN | -19.0% |
2018 FY | -10.77 Million PLN | 0.0% |
2017 Q4 | - PLN | 0.0% |
2017 Q1 | - PLN | 0.0% |
2017 FY | - PLN | 0.0% |
2017 Q3 | - PLN | 0.0% |
2016 FY | - PLN | 0.0% |
2015 FY | - PLN | -100.0% |
2014 FY | 1.3 Million PLN | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Bioceltix S.A. | 76.33 Thousand PLN | 100.0% |
BIOTON S.A. | 12.67 Million PLN | 100.0% |
Captor Therapeutics Spolka Akcyjna | 1.24 Million PLN | 100.0% |
Mabion S.A. | 2.94 Million PLN | 100.0% |
Molecure S.A. | 4.97 Million PLN | 100.0% |
Pharmena S.A. | 114 Thousand PLN | 100.0% |
Poltreg S.A. | 7.8 Million PLN | 100.0% |
Pure Biologics Spólka Akcyjna | 12.85 Million PLN | 100.0% |
Ryvu Therapeutics S.A. | 365 Thousand PLN | 100.0% |
Synthaverse S.A. | 61.2 Million PLN | 100.0% |
Urteste S.A. | 312 Thousand PLN | 100.0% |